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Abstract
Purpose—Over the last decade, few novel antibiotics have been approved by the Food and Drug 
Administration (FDA) for pediatric use. For most anti-infective agents, including antibiotics, 
extrapolation of efficacy from adults to children is possible if the disease and therapeutic 
exposures are similar between the 2 populations. This approach reduces the number of studies 
required in children, but relies heavily on exposure matching between children and adults. Failures 
in exposure matching can lead to delays in pediatric approvals of new anti-infective agents. We 
sought to determine the extent of exposure matching, defined by a comparison of area under the 
concentration-time curve, between children and adults, for anti-infective drug products submitted 
to the FDA for approval.
Methods—We reviewed anti-infective submissions to the FDA (2002–2014) for pediatric 
indication. We included drug products administered via oral, intravenous, or intramuscular 
administration routes, and those with AUC estimates for children in available FDA reports. Our 
main outcome of interest was the proportion of drugs with median (or mean) pediatric AUC within 
20% of the median (or mean) reported adult value.
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Findings—We identified 29 drug products that met inclusion criteria, 14 (48%) of which had 
mean (or median) AUCs of all submitted age groups within 20% of that in adults. Only route of 
administration and drug class were associated with pediatric AUC within 20% of adult AUC.
Implications—Future research is needed to define criteria for and predictors of successful 
exposure matching of anti-infectives between children and adults.
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INTRODUCTION
In the United States, recent legislation has aimed to address deficiencies in pediatric drug 
product labeling. Through the Best Pharmaceuticals for Children Act (BPCA), sponsors are 
provided incentives to submit pediatric pharmacokinetic (PK) and pharmacodynamic (PD) 
studies of drugs in children.1 These incentives have resulted in an expansion of pediatric 
clinical research, submission of pediatric data to the Food and Drug Administration (FDA), 
and pediatric labeling changes, including 466 changes after the initial BPCA renewal in 
2002.2
Despite the large number of label changes, a substantial number of pediatric clinical trials 
have failed to meet their proposed objectives. In one analysis of 158 studies conducted to 
obtain pediatric drug labels, 18% of drug products were not labeled for pediatric use, and 
6% were labeled for pediatric use but not for the studied indication.3 Potential reasons for 
these failures include lack of appropriate dosing range, lack of efficacy, lack of pediatric 
formulation, trial design failure, insufficient sample size, and poor dose selection.3–5
To improve the success of pediatric submissions and to ensure appropriate allocation of 
limited resources, the FDA developed a pediatric study planning and extrapolation algorithm 
that provides guidance for industry about the necessary studies required for drug approval 
for a pediatric indication.6 According to this algorithm, if the disease progression and 
response to intervention are expected to be similar between children and adults, required 
clinical trials are limited to those that evaluate the PK and safety of the drugs. This is true for 
most anti-infective agents. Therefore, the goal of PK studies for anti-infectives is to identify 
doses in children that result in drug exposures shown to be efficacious in adults. Achieving 
similar drug exposures between children and adults (i.e., exposure matching) is paramount 
to extrapolation of efficacy from adult studies.
Given the need to achieve exposure matching between children and adults, one of the most 
important reasons for failure to obtain pediatric approval for anti-infectives is poor dose 
selection that occurs early in the drug development process.4 Therefore, pediatric drug 
development may have improved efficiency and success as well as decreased costs if doses 
for early phase trials are more appropriately selected.
Available methods for dose selection using adult data include population PK models, which 
incorporate allometric scaling, maturational and organ functions, and physiologically based 
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PK modeling, among others. It is unclear in public reviews, which of these methods, if any, 
sponsors are using for pediatric drug development. Further, although several FDA guidance 
documents discuss approaches for matching systemic exposure between two 
populations,7–11 there is no well accepted approach for evaluating matching between adult 
and pediatric populations. We sought to describe the extent to which area under the 
concentration versus time curve (AUC), a well-accepted measure of average drug 
concentration over a time period,12 was comparable between children and adults using 
publicly available data.
METHODS
Data Sources
Since 2002, medical, clinical pharmacology, and statistical review documents are regularly 
published on the FDA website for each pediatric submission.13 The medical and clinical 
pharmacology review documents describe or summarize studies that were conducted to 
obtain pediatric approval.
We identified all anti-infective drug products submitted to the FDA for a pediatric indication 
and available online in the FDA websites from January 1, 2002 through August 28, 2014. 
We reviewed clinical pharmacology and medical review reports for each anti-infective 
submission. If available documentation on the FDA website was incomplete, we retrieved 
publications from PubMed related to the referenced studies in the FDA reports.
We extracted anti-infective characteristics including known pathways of elimination from 
the FDA product label or drug reference applications (i.e., Micromedex®, Lexicomp®, 
DailyMed [http://dailymed.nlm.nih.gov]).
Inclusion/Exclusion Criteria
The unit of observation to identify exposure matching between children and adults was the 
drug submitted for pediatric approval. We included an anti-infective in our analysis if it met 
the following criteria: 1) oral, intravenous, or intramuscular administration; and 2) inclusion 
of AUC estimates in available reports for pediatric age groups of interest. Submissions for a 
new physical design of a previously approved drug product (e.g., new scored tablet, 
previously unscored) were not eligible for inclusion.
The unit of observation to identify anti-infective trial characteristics associated with 
exposure matching was a trial submitted to support an application. We included an anti-
infective trial in our analysis if the trial was the first to describe a drug’s PK/PD properties in 
a pediatric age group.
Definitions and Outcomes
We used area under the curve from time zero to infinity (AUC0-∞) or zero to a given time 
point (AUC0-t) available in drug submissions to determine exposure matching between 
children and adults. We preferentially extracted median values if available for both children 
and adults, followed by geometric mean, and then arithmetic mean.
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For individual drugs, we described exposure matching between children and adults by the 
following criteria: 1 median (or mean) pediatric AUC within 20% of the reported adult 
value; 2) median (or mean) pediatric AUC within 50% of the reported adult value; or 3) 
≥75% of pediatric AUC ranges within the reported adult range. Pediatric exposure was 
defined as “within 20% of the median (or mean) adult exposure” if the ratio of the pediatric 
to adult AUC was 0.8 to 1.2 for all age groups in which sponsors were seeking approval. For 
example, the sponsor for caspofungin sought approval for ages 3 months to 17 years. We 
extracted median values to calculate the AUCchild/AUCadult ratio for each of the following 
age groups: 3–24 months, 2–11 years, and 12–17 years. If a single value of AUCchild/
AUCadult ratio in any of these age groups did not meet our predefined criteria (0.8–1.2), we 
classified the drug as not being within 20% of the adult median exposure. Similarly, we 
calculated exposure matching within 50% using an AUCchild/AUCadult ratio of 0.5 to 1.5.
Pediatric AUC ranges were 1) defined as the median and observed range of values if 
available for both children and adults for a given drug, or 2) calculated as the mean AUC ± 2 
standard deviations for a given age group if median and range were not available. The 
default adult AUC was obtained from the reported value in healthy volunteers unless 
medical and PK reports specifically noted that exposure from patients was used as the target 
for exposure matching. If adult exposure was not reported in the FDA documents, pediatric 
exposures were compared to the most liberal (values closes to pediatric values) data in 
healthy adults identified in the FDA product label. We determined the percentage of the 
AUC range for each age group (e.g., 3–24 months, 2–11 years, and 12–17 years for 
caspofungin) that was within the calculated AUC range for adults. We summarized drug 
exposure matching according to whether ≥75% of the AUC ranges for the entire pediatric 
age range was within the calculated adult range. Each age group was weighted according to 
the number of years it contributed to the overall drug submission. For example, the 
caspofungin 2–11 years age group accounted for ~60% of the total age submission (10 years 
in this range/17 total years in the submission = 0.60). The AUC range for this age group was 
0.70 of the adult range, and the weighted value was 0.42 (0.70 × 0.60). The sum of weighted 
values for all age groups submitted (3–24 months, 2–11 years, and 12–17 years) determined 
whether caspofungin was classified as having ≥75% of the pediatric AUC range within the 
adult range.
We also directly compared exposure matching by AUCchild/AUCadult ratio and range of 
AUCchild/AUCadult ratios for each anti-infective trial that determined drug exposure in the 
following FDA-defined pediatric age groups: neonates (<1 month), infants (1 month to <2 
years), children (2 to <12 years), and adolescents (12 to 16 years). We presented the data in 
graphical form for each age group.
Data Collection
We collected specific application, drug product, and trial details for each anti-infective. In 
addition to exposure-matching data, we extracted the following details from the FDA 
reports: 1) sponsor requests and FDA approval of new or expanded anti-infective indications 
for all age groups of interest; 2) routes of administration and elimination; 3) anti-infective 
class (antiviral, antibacterial, antifungal); 4) year of pediatric anti-infective approval; 5) drug 
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development phase of clinical trial in which sponsors collected qualifying PK/PD data; 6) 
PK data analysis methods; 7) extrapolation of efficacy from studies in adults; and 7) method 
the sponsors used to determine dose in the PK/PD clinical trial. For the method used to 
determine dose, we specifically noted whether prior to trial initiation, a sponsor explicitly 
mentioned or described use of the following methods: 1) scaled the adult dose to children 
using a body size measure (e.g., linear or allometric) or applied a maturational function; 2) 
developed a strategy to evaluate multiple different doses/dose combinations within one study 
to determine the correct pediatric dose; or 3) used data from a previous pilot study of PK/PD 
properties in children.
Statistical Analyses
We used standard summary statistics, including percentages, means, and ranges, to describe 
the study variables. Fisher’s exact tests were used to compare exposure matching by anti-
infective and trial characteristics. We used linear regression and Cochran–Armitage tests for 
trend to identify directionality of significant results. We used STATA 13.1 (StataCorp LP, 
College Station, TX, USA) for all statistical analyses and considered a P-value < .05 
statistically significant.
RESULTS
We reviewed 55 applications for 51 anti-infectives submitted to the FDA for approval 
(Figure 1). For 4 of the submitted anti-infectives (8%), we retrieved publications from 
PubMed regarding trials conducted and submitted to the FDA. Of the 51 evaluated anti-
infectives, 12 (24%) were topical formulations and 10 had limited AUC information 
specifically available for the population of interest. Of the 10 drugs excluded for limited 
AUC information, 5 (50%) were antivirals. The remaining 29 anti-infectives (54%) met our 
criteria for analysis. Sponsors submitted applications to solely obtain a new pediatric 
indication for 20/29 anti-infectives and to solely expand the pediatric indication for 6/29 
anti-infectives. Darunavir and tenofovir each had one submission for a new pediatric 
indication and a second to expand the pediatric indication, while atazanavir had 2 
submissions, each to expand the pediatric indication. The majority of anti-infectives were 
antivirals (21/29, 72%), indicated for HIV (14/29, 48%), and administered orally (23/29, 
79%) (Table I).
Among the 29 anti-infectives, exposure matching by median (or mean) AUC was variable. 
Considering initial PK trials for anti-infectives included in this study, 14 anti-infectives 
(48%) had a median (or mean) AUC of all submitted age groups within 20% of that in 
adults, while 22 (76%) had a median (or mean) AUC within 50% of that in adults (Table II). 
Route of administration and anti-infective class were the only statistically significant 
differences between matched and unmatched drugs within 20% (Table III). All anti-
infectives that had a median (or mean) AUC within 20% were orally administered, and 
13/14 (93%) were antivirals. All anti-infectives that sought approval for only adolescents (4 
drugs) matched adult and pediatric median (or mean) exposures within 20%.
Exposure matching by AUC range criteria was also variable. Range data were available or 
able to be calculated for all anti-infectives except darunavir. Fourteen (48%) drugs had ≥1 
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submitted age group in which the pediatric AUC range was completely within the published 
adult range. Fifteen anti-infectives (52%) had ≥75% of the pediatric AUC ranges within the 
adult range. Compared to antibacterial drug class and intravenous route of administration, 
antiviral drug class and oral route of administration were indicative of exposure matching by 
the 75% range criteria. Eleven anti-infectives (44%) were within 20% of the adult mean (or 
median) and met the 75% range criteria.
The variability in exposure matching by our criteria is magnified when the drugs are 
classified by age, according to the following groups: neonates (< 30 days), infants (1 month 
to <2 years), children (2 to 11 years), and adolescents (12 to 16 years) (Figure 2).
Of the 29 anti-infectives included in our analysis, all but 3 (atazanavir without ritonavir from 
2007 submission, famciclovir, and nelfinavir) received FDA approval for the entire age 
range for which sponsors were seeking approval. Among the anti-infectives that were 
approved, mean (or median) AUCs for children were within 20% of adult AUCs for 46% of 
anti-infectives. Similarly, ≥75% of the child AUC range was within the adult range for 54% 
of approved anti-infectives. Of the anti-infectives that were approved, 12/26 (46%) relied on 
some extrapolation of efficacy from adult studies. Of these, 5 (42%) anti-infectives matched 
exposure by mean AUC 20% or range criteria.
Finally, we examined trial characteristics that might influence the similarity between 
pediatric and adult exposures. In total, we analyzed 39 trials. Non-compartmental analysis 
was the predominant method of PK analysis (23/39 trials, 59%). To determine the dose 
studied in the pediatric trial, sponsors commonly scaled by body size or applied an age-
dependent organ function (e.g., creatinine clearance) to the adult dose (20/39, 51%). Of 
these 20 studies, 6 studies (30%) scaled the adult dose using body weight, 9 (45%) used 
body surface area, 4 (25%) used the equivalent adult dose in adolescent populations, and 1 
(5%) used an age-dependent maturational factor to determine the dose. Phase of trial, 
method of PK analysis, and overall method of initial dose determination (e.g., application of 
a body size measure or applied maturational function, strategy to evaluate doses within one 
study, or use of pilot data) were not associated with exposure matching. However, all trials 
that used body weight-based dosing met mean AUC 20% criteria, and 78% of trials that used 
body surface area did not meet this criteria (P = .007).
DISCUSSION
According to our results, differences in exposure matching by AUC occurred in the initial 
pediatric PK studies of ≥50% of the anti-infectives evaluated in this study. Because this 
study focuses on the early stages of pediatric drug submission, we cannot comment on 
exposure matching for the FDA-approved dose. However, FDA approval occurred for most 
drugs in our study. The observed discrepancy between exposure matching in initial PK 
studies and drug approval could be because 1) anti-infective approval does not rely on 
information obtained from exposure matching in early PK studies alone or on information 
included in publicly available reports; 2) anti-infective approval does not rely on our 
definition of exposure matching; 3) exposure measures other than AUC were used for 
exposure matching; 4) anti-infective approval relies on exposure matching information in 
Zimmerman et al. Page 6
Clin Ther. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
some pediatric sub-populations to grant approval for the whole pediatric population; or 5) 
pediatric exposures should be different from those in adults given discrepant therapeutic 
indices or possibilities for drug resistance, between the two populations.3,5–11,14,15
It is likely that exposure matching does not rely on our definition; to date, criteria for 
exposure matching between children and adults for pediatric drug approvals have not been 
defined in the United States.7–11 Instead, sponsors define their own targets for exposure 
matching for each drug product. The result of this method is variability in the exposure 
measure of interest and variability in acceptable parameters for exposure matching. For 
example, this variability is evident in the submissions for adefovir and fosempranavir. For 
adefovir exposure in children, sponsors targeted the adult maximum concentration (Cmax, 
18.4 ng/mL) and AUC0-∞ (230.3 ng*hr/mL); however, sponsors did not explicitly define the 
minimum and maximum acceptable values of Cmax or AUC0-∞. In contrast, sponsors more 
clearly defined the targets for fosemprenavir, ranging from the 25th percentile for 
concentration at a defined time-point (Ctau) to the 95th percentile for AUC observed in 
healthy adults.
In contrast to the variable definitions for exposure matching observed in submissions to the 
FDA, we defined specific criteria that we applied to all anti-infective submissions. In 
defining these criteria, we considered PK and drug exposure variability. Exposure matching 
using summary data alone (e.g., median or mean AUC for a given population) is risky in 
children because it oversimplifies the population under study. Most pediatric early phase 
studies are small, are conducted in patients with the disease, and may include a relatively 
wide age range. These factors all increase the variability in observed exposures. Therefore, it 
is possible for a drug in children to have, on average, very similar exposures to adults, but in 
reality have only toxic or sub-therapeutic exposure ranges. This discrepancy between 
average exposures and ranges of exposures may be even more pronounced if you examine 
exposure matching by age, as depicted in Figure 2.
Possible discrepancy between average values and ranges as well as variability in the extent 
of exposure matching by our criteria suggest the need to consider several key factors in the 
development of formal exposure-matching criteria for children and adults. These factors 
include 1) the ideal primary exposure measure for exposure-matching analysis (this will 
likely vary by drug), 2) use of individual compared to summary data to calculate exposure 
matching, 3) the need for varying criteria by pediatric age group based on underlying 
variability in drug disposition, and 4) consideration of a drug’s therapeutic index.
Although it is clear that the development of defined criteria for exposure matching between 
children and adults is necessary, it is less clear what drug or trial characteristics influence 
exposure matching according to the defined criteria. We anticipated that age of the 
population of interest (e.g., only adolescents or only children and adolescents compared to 
neonates) and method of dose determination would greatly influence the extent of exposure 
matching. In a recent analysis, 87/92 (95%) of drug products submitted to the FDA had 
recommendations for equivalent dosing of adolescent and adult patients.16 However, age 
was not a statistically significant determinant of exposure matching by our criteria.
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Method of dose determination was not associated with exposure matching by our criteria 
despite known developmental changes in body composition and maturation in organ 
function that occur with age and should influence method of dose determination.17,18 For 
example, scaling of adult dosing to pediatric patients using allometric principles can account 
for differences in developmental PK for children >2 years of age; however, empirical models 
using maturational functions or physiological models based on in vitro data are typically 
needed to describe drug disposition in younger children.19,20 Reasons for lack of association 
between age or method of dose determination and exposure matching may include: 1) 
limited number of anti-infectives included in our analysis (29/51 met inclusion and 
exclusion criteria); 2) skewed distribution of age groups of interest among anti-infectives 
(e.g., 4 studies including neonates, and 4 studies that included only adolescents); and 3) 
sponsors’ use of maturational factors or physiological principles in appropriate populations.
The limitations of our study include 1) a limited number of anti-infectives that met inclusion 
and exclusion criteria, 2) availability of predominantly HIV drugs for analysis, where 
concerns about drug toxicity may disproportionately influence dose selection in early phase 
trials, 3) limited ability to capture additional factors (e.g., study sample size and variation in 
ages) that potentially influence successful exposure matching, 4) ability to extract only 
information that was publicly available, which may have varied by drug, 5) lack of 
consistency in the content and structure of documents submitted to the FDA, 6) access to 
summary-level data and not patient-level data, 7) inclusion of AUC as the only measure of 
successful exposure matching, and 8) inability to determine clinical relevance of our defined 
criteria for exposure matching.
Access to only summary-level data and inclusion of only AUC data are likely the most 
important of these limitations. Use of summary data mandated calculations to obtain AUC 
ranges for children and adults; however, this method may not have reflected actual observed 
minimum and maximum AUC values. Further, although AUC is one of the most widely 
available PK parameters for anti-infectives and other drug classes, it is unknown whether 
AUC is the best PK parameter to determine exposure matching.14 For many anti-infectives, 
PK/PD indices that have been predictive of antimicrobial efficacy include Cmax/minimum 
inhibitory concentration (MIC), AUC/MIC, time above MIC, or trough concentration/half 
maximal inhibitory concentration.15 Given the specific interest in extrapolation of efficacy 
from adult to pediatric populations, such parameters with proven association to efficacy may 
be more relevant than AUC alone.
CONCLUSIONS
Despite certain limitations, our study highlights several areas for improvement in exposure 
matching of adult to pediatric anti-infectives. These areas for improvement include the need 
to 1) define criteria for successful exposure matching that accounts for PK variability in 
pediatric populations; 2) design trials, accounting for developmental changes that affect drug 
disposition; 3) improve granularity and standardization of sponsor submissions to the FDA; 
and 4) concentrate resources on exposure matching and reduce studies of pediatric efficacy 
for drugs that may extrapolate efficacy from adult data. The ability to address these areas in 
future studies may increase the likelihood of success in obtaining a pediatric indication, 
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improve the breadth of pediatric labeling, and help to conserve limited financial resources 
that are currently available for research in pediatric therapeutics.
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Figure 1. 
Flow chart of drug inclusion in the final analysis.
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Figure 2. 
Comparison of pediatric to adult area under the concentration-time curve (AUC) without 
outliers: age (A) <30 days, (B) 1 month–<2 years, (C) 2–11 years, and (D) 12–16 years. 
Drug products were considered outliers and excluded from the figure if the range of ratios 
for the drug product was > 2.5 SD of the range of ratios for the age group of interest. 
Multiple studies for a single drug will have the same identifying number (e.g., 3 studies 
supporting the 2–11 age group for a drug will be located on the x-axis at 7.0, 7.4, 7.8). Blue 
dots represent the AUCchild/AUCadult median (or mean) ratio. The solid black line represents 
the equivalence median (or mean) AUC between children and adults (ratio=1). Horizontal 
dashed lines represent the upper and lower bounds of a normalized adult AUC range. Ratios 
and ranges that fall within the dashed lines indicate pediatric AUC values within the adult 
range.
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Table II
Comparison of Median (or Mean) AUC and AUC Ranges for Anti-infectives in Children and Adults
Drug Within 20% Adult Mediana Within 50% Adult Mediana
% Pediatric Range Within Adult 
Rangeb
Adefovir Yes Yes 78–100
Amoxicillin Clavulanate XR No Yes 40–81
Atazanavir w/o ritonavir No No 71–100
Atazanavir w/ ritonavir Yes Yes 100
Azithromycin No No 42–100
Caspofungin No Yes 60–73
Darunavir Yes Yes n/a
Dolutegravir Yes Yes 93
Efavirenz Yes Yes 94
Emtricitabine Yes Yes 43–79
Entecavir Yes Yes 81–100
Ertapenem No Yes 3–8
Etravirine No Yes 97–100
Famciclovir No No 0–100
Fosamprenavir No Yes 31–45
Levofloxacin No No 0–100
Linezolid No No 0–44
Lopinavir/ritonavir No No 53–100
Micafungin No No 28–49
Nelfinavir Yes Yes 66–90
Oseltamivir Yes Yes 85–100
PEG-Interferon alfa-2b + ribavirin No Yes 52–56
Raltegravir Yes Yes 23–61
Ritonavir Yes Yes 44–67
Tenofovir Yes Yes 73–100
Terbinafine Yes Yes 88–100
Tipranavir No Yes 59–93
Valacyclovir Yes Yes 71–100
Valgancyclovir No Yes 55–100
Abbreviation: AUC, area under the concentration-time curve.
a
Mean values used if medians were unavailable.
b
Presented as a range of percentages (e.g., 78–100) to account for variability in each age groups of interest for a specific drug. For example, 0 to 4 
year olds for drug A may have a pediatric range entirely within the adult range (i.e., 100%), but only 78% of the range for 5 to 8 year olds is within 
the adult range. This is listed as 78–100.
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Table III
Drug Characteristics Associated With Median Pediatric AUC Within 20% of Median Adult AUCa
AUCchild/AUCadult ratio 0.8–1.2
N = 14
AUCchild/AUCadult ratio < 0.8 or > 1.2
N = 15
Route of administration, No. (%)
 Oral 14 (100) 9 (60)
 Intravenous 0 3 (20)
 Both 0 2 (13)
 Other 0 1 (7)
Route of elimination, No. (%)
 Renal unchanged 5 (36) 2 (13)
 Hepatic then renal 2 (14) 7 (47)
 Hepatic then fecal 7 (50) 5 (33)
 Other 0 1 (7)
Indication, No. (%)
 HIV 9 (64) 5 (33)
 Intra-abdominal 1 (7) 1 (7)
 Systemic 3(21) 5 (33)
 Candidiasis 0 2 (13)
 Other 1 (7) 2 (13)
Drug class, No. (%)
 Antiviral 13 (93) 8 (53)
 Antibacterial 0 5 (33)
 Antifungal 1 (7) 2 (13)
Age range, No. (%)
 Only 12–17 years 4 (29) 0
 > 2 years 5 (36) 5 (33)
 > 28 days 3 (21) 8 (53)
 > birth 2 (14) 2 (13)
Year approved, No. (%)
 > 2008 8 (57) 13 (87)
 < 2008 6 (43) 2 (13)
Approved indication, No. (%) 13 (93) 13 (87)
Abbreviation: AUC, area under the concentration-time curve.
a
Mean values used if medians were unavailable
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